FDA issues new guidelines for transmucosal delivery of pain drug

As of Dec. 29, the FDA has placed every product featuring the transmucosal delivery of fentanyl under a single Risk Evaluation and Mitigation Strategy, also known as REMS. Fentanyl is used to treat cancer-related pain when other medicines don't work. A REMS program guides how a drug is made available to patients to protect their health and limit drug abuse. The decision is expected to help companies such as BioDelivery Sciences International ($BDSI), which makes a product that delivers fentanyl through a film placed on the inside of the cheek, reports MedCityNews.com. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.